Skip to content

Ultrafine Particles and Fetal Contamination

Study of the Permeability of Atmospheric Particles Placenta (Fine and Ultrafine Particles): Analysis of Fetal Retention

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04068389
Acronym
FOETOPUF
Enrollment
62
Registered
2019-08-28
Start date
2009-12-22
Completion date
2012-11-09
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung; Premature, Pollution; Exposure

Keywords

Atmospheric particles

Brief summary

The objective of this study is to evaluate the transplacental passage of fine and ultrafine particles (nanoparticles) inhaled by the mother.

Detailed description

Epidemiological studies have demonstrated the harmful effects of particulate air pollution on the progress of pregnancy and postnatal health. Experimental studies have suggested the transplacental passage of asbestos fibers, but despite the strong growth in the use and production of fine and ultrafine particles, no study has examined the permeability of the placenta to these compounds or the exposures fetuses that may result. The objective of this study is to evaluate the transplacental passage of fine and ultrafine particles (nanoparticles) inhaled by the mother.

Interventions

PROCEDUREPulmonary Tissue Collection

Pulmonary Tissue Collection

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE

Inclusion criteria

\- All women volunteers for whom a medical termination of pregnancy is proposed for a fetus older than 22 weeks (weight over 500g).

Exclusion criteria

* Refusal of participation of the patient. * Fetus with malformation syndrome affecting pulmonary perfusion.

Design outcomes

Primary

MeasureTime frameDescription
Presence of fine particles in fetal lung samples yes/noAt the screeningAnalysis in electron microscopy

Contacts

PRINCIPAL_INVESTIGATOROlivia OCHRYMCZUK, Dr

University Hospital, Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026